Emerging treatments
Venetoclax
Venetoclax is an oral B-cell lymphoma-2 (BCL-2) inhibitor. In a phase 2 trial of 32 patients (all patients MYD88 L265P-mutated; 17 with CXCR4 mutations; 16 previously exposed to Bruton tyrosine kinase [BTK] inhibitors), overall, major, and very good partial response rates were 84%, 81%, and 19%, respectively.[114] Response to venetoclax was durable, with median progression free survival of 36 months.[115]
Pirtobrutinib
Pirtoburinib, a noncovalent third-generation Bruton tyrosine kinase (BTK) inhibitor, has been granted accelerated approval for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.[116][117] A single-arm, open-label, phase 2 study to evaluate the safety and efficacy of venetoclax combined with pirtobrutinib in participants with symptomatic Waldenström macroglobulinemia with previously treated disease, is currently recruiting.[118]
Use of this content is subject to our disclaimer